Depression represents a major public health problem. It is estimated that 13-20% of the population has some depressive symptoms at any given time and about 5% of the population is assumed to suffer from major depression. Known pathological processes include ischemia, neoplasia, necrosis, apoptosis, infection, and inflammation. Of those, inflammation is the most compatible with the waxing and waning course of depression, and could explain the biology of this disorder that has a fluctuating course with severe episodes that can be followed by partial or complete remission. Over the years a body of evidence has been accumulated suggesting that major depression is associated with dysfunction of inflammatory mediators. Major depression commonly co-occurs with ischemic heart disease and decreased bone mineral density. Depressive symptoms are known to have a negative impact on cardiovascular prognosis, increasing the mortality rate of coronary artery disease. Several lines of evidence indicate that brain cytokines, principally interleukin-1␤ (IL-1␤) and IL-1 receptor antagonist may have a role in the biology of major depression, and that they might additionally be involved in the pathophysiology and somatic consequences of depression as well as in the effects of antidepressant treatment. A particularly unique and novel aspect of the studies and views discussed here is their potential to lead to interventions which may reduce the morbidity and mortality risks for osteoporosis, cardiovascular disease, and behavioral symptoms in patients with major depression. We also discuss the emerging concept of peripheral and central cytokine compartments: their integration and differential regulation is a key element for the optimal functioning of the immune and nervous systems.
Introduction
The contributions of immune mediators to the pathogenesis, pathophysiology, and treatment of psychiatric disorders have been studied for over 100 years. The only Nobel Prize ever awarded to a psychiatrist was granted to Julius Wagner-Jauregg, University of Vienna, Austria, in 1927 for his work on the changes achieved in the course of mental illness through the activation of the immune system by an infectious agent. Already in 1887 he systemically investigated the effects of febrile diseases on psychoses, later making use of tuberculin (discovered in 1890 by Robert Koch). As this and similar methods of treatment did not yield satisfactory results, he turned in 1917 to malaria inoculation, which proved to be very successful in the case of dementia paralytica. This discovery earned him the Nobel Prize in 1927. Writing in The Lancet in 1998, TN Raju states that 'Wagner-Jauregg regarded mental illnesses as biological entities for which he sought 'physical' cures. In this regard, his views-though not his remedies-seem contemporary'. 1 We would add that the contemporaneity of Wagner-Jauregg's views can be attested to, not only by the general concept of mental illness as biological entities, but also by the specific data-based hypothesis that biological mediators primarily designed to combat pathogens may affect the course of mental disorders. Even though it has been widely recognized for over 70 years that immune mediators have profound effects on the course of psychiatric disorders, the pathways and mechanisms by which immune mediators affect key brain functions that are dysregulated in psychiatric disorders are just now beginning to be elucidated. 2 It would make intuitive sense that immune mediators might be a key element of the biology of affective disorders. The most logical starting point in the search for a biological basis for mood disorders is a review of the known pathological processes that result in disease. Unless depression is caused by a novel-as yet unknown-process, a careful analysis of existing pathological mechanisms is warranted. Those include ischemia, necrosis, apoptosis, inflammation, infection, hyperplasia, dysplasia, neoplasia, genetically-based structural or functional (enzymatic) defects, and nutritional imbalances, including undernutrition and overnutrition (obesity and atherosclerosis). 3 Of those processes, inflammation is the most compatible with the clinical course of depression, which can last decades with periods of serious relapse intermixed with periods of remission, of varying duration and intensity. Such a waxing and waning course is characteristic of inflammation. At the present time, a growing body of circumstantial evidence exists that suggests that major depression is associated with dysregulation of immune mediators. [4] [5] [6] It has been suggested that cytokine hypersecretion may be involved in the pathophysiology of depressive disorders. 7 Cytokines are a large and diverse group of pleiotropic and redundant polypeptides with important established and emerging roles in central nervous system (CNS) function and pathology. Cytokines have been reported to be involved in various key CNS functions that are dysregulated in major depression, such as sleep, food intake, cognition, behavior, temperature and neuroendocrine regulation. For the last 10 years several groups, including ours, have tested the hypothesis that dysregulation of brain cytokine signalling could contribute to the neurobiology of depressive disorder. The hallmarks of cytokine biology are redundancy and pleiotropism. However, as most cytokines and chemokines can be expressed in the nervous system, it becomes impractical to study or to review all of them in the same setting. Thus, the focus of this article will be interleukin (IL) 1-related molecules.
IL-1 action is regulated by a network of molecules that form a complex system (IL-1 system) that includes several ligands [IL-1␣, IL-1␤, 8, 9 and IL-1 receptor antagonist (IL-1ra)], 10,11 many binding sites [IL-1 receptor type I (IL-1RI), 12 IL-1RII, 13 IL-1 accessory protein, 14 soluble receptors, 15 receptor-related proteins, 16 receptorlike molecules, 17 and autoantibodies], and a regulatory enzyme [IL-1␤ converting enzyme (ICE) or caspase 1] (for review refer to Dinarello, 1996 18 ). The signal-transducing IL-1 type I receptor (IL-1RI) has a long intracellular domain, while the type II receptor (IL-1RII), which has a short intracellular domain, does not transduce a signal, functions as a decoy for bioactive IL-1, and is upregulated by anti-inflammatory agents such as anti-inflammatory cytokines (eg, IL-13) and steroids. 19 A unique component of this system is IL-1ra, the first pure endogenous receptor antagonist to be discovered.
Cytokines can act in the brain through one or more of the following mechanisms: (1) disruption of the bloodbrain barrier (BBB); (2) penetration in the brain through circumventricular organs (these sites in the brain have capillaries with open junctions and abundant fenestrations); (3) de novo synthesis in the CNS; (4) action in peripheral nerves which signal the brain. It is still not known which of these mechanisms, that are not mutually exclusive, are involved in specific pathophysiological situations. 20 Brain cells, including neurons, microglia, endothelial cells and astrocytes can produce IL-1␤ in response to various physiological and pathological stimuli. IL-1␤ adminstration in the CNS has been reported to produce 'stress-like' effects on behavior, food intake, monoamine neurotransmitters, hypothalamic pituitary adrenal axis activity and immune function. [21] [22] [23] [24] [25] [26] [27] [28] IL−1 is a potent stimulus to corticotropinreleasing hormone (CRH) production, resulting in activation of the hypothalamic-pituitary-adrenal (HPA) axis. 29, 30 CRH hypersecretion is a well replicated finding in depression. It is tempting to speculate that CNS cytokines are responsible for CRH dysfunction and for the intermittent pattern of hypothalamic dysfunction that is characteristic of depression and that is consistent with the waxing and waning course of disorders mediated by cytokines. Moreover, IL-1␤ has been reported to be a potent regulator of the serotonin transporter gene. 31 This finding is quite relevant because: (1) the serotonin transporter expressed in brain, platelets, and placenta is a primary target for antidepressants, cocaine, and amphetamines; and (2) upregulation of the expression of the human serotonin transporter gene by a physiologically occurring hormone/cytokine has not been described before.
The typical action of the prototypical cytokine IL-1 in the CNS is fever, but several CNS functions, such as sleep, food intake, cognition, behavior, and neuroendocrine regulation are influenced by IL-1 and other cytokines; those functions are dysregulated in patients with major depression. Dysregulation of food intake and body weight is an important manifestation of major depression. We have proposed that the adipocyte cytokine leptin 32 may contribute to the manifestations of depression and that agents that regulate leptin bioactivity might be of use in the treatment of major depression. 33 Luheshi et al 34 have recently shown that IL-1 signal transduction is required for the effects of leptin on body weight. Those authors showed that IL-1␤ treatment induced immunoreactive IL-1 in the hypothalamus. They also showed that wild-type animals treated with IL-1 receptor antagonist and mice with a knockout for the IL-1RII do not exhibit the same level of weight loss after leptin treatment that is achieved in animals with intact IL-1 bioactivity. 34 Thus, central IL-1 production appears to be required for the regulation of body weight by leptin. Further studies are needed to test the hypothesis that leptin acting through IL-1 might mediate the dysregulation of body weight that occurs in depressive disorder.
Several lines of evidence suggest that endogenous IL-1 can also mediate neurodegeneration in the rat brain. Moreover, IL-1 can disrupt the BBB, 35 38 Likewise, neurotrophic and protective effects of cytokines in brain neurons have been clearly described. It has been observed that brain cytokines are upregulated in many neurological disorders, including Alzheimer's disease, Downs' syndrome, multiple sclerosis, temporal lobe epilepsy, Parkinson's disease and human immunodeficiency virus infections. [39] [40] [41] Thus, depending on amount and site of expression, cytokines can be either neuroprotective or neurotoxic. Evidence indicates that at high levels, in the context of acute events, IL-1␤ is neurotoxic. Recent data in models of acute brain ischemia suggest that local increases of CRH contribute to acute neurodegenerative processes, 42 while IL-1ra synthesis is involved in the process of neuroprotection; 43 therefore, it is likely that the actions of IL-1 are also mediated through CRH in extrahypothalamic sites.
In the periphery, cytokines are known to influence bone metabolism, inflammatory response and possibly cardiovascular disease. So, it is possible that while brain cytokines may be involved in the pathophysiology of some aspects of major depressive disorder, peripheral cytokines might be implicated in the long-term medical consequences of major depression (eg osteoporosis and cardiovascular disease). Studies to unravel neuroimmune interactions could lead to a search for interventions that may reduce the morbidity and mortality risks for osteoporosis, cardiovascular disease and behavioral symptoms in patients with major depression.
Identification of cytokine expression in the brain
The first experiments that localized cytokine gene expression in rat brain were conducted in the 1980s. IL-1 was localized in human hypothalamus by Saper's group. 44 That was followed by the localization of the mRNAs encoding signal-transducing IL-1 receptor in mouse brain 45 and IL-1-ra in the rat brain. 46 Those findings have been replicated by a number of subsequent studies. 47 IL-1RI mRNA was localized in rat brain, 48, 49 particularly in vascular areas 50 by in situ hybridization histochemistry (ISHH). 48, 49 Other components of the IL-1 system have also been localized in vascular areas in the rat brain. 51, 52 Several other cytokines and cytokine receptors have since been also localized in the brain. Given the important role of IL-1 bioactivity in regulation of HPA function and behavior, several investigators have conducted studies to address key questions related to the role of IL-1ra in the brain.
Functional characterization of an endogenous cytokine
Endogenous IL-1ra is neuroprotective IL-1ra is a naturally occurring pure endogenous antagonist of IL-1 actions. IL-1ra transcription and translation occur in the brain. Exogenous IL-1ra administration was neuroprotective in animal models of stroke, 53 whilst intracerebroventricular infusion of IL-1 increased ischemic brain damage. Based on those data, it was hypothesized that IL-1ra might be an endogenous neuroprotective molecule. That hypothesis was tested in studies of middle cerebral artery occlusion (MCAo): cerebral expression of IL-1ra was induced rapidly by focal cerebral ischemia or brain trauma in rats, and inhibition of the action of IL-1ra, by passive immunoneutralization, markedly enhanced damage. 43 Therefore, endogenous IL-1ra can be induced by acute neurodegenerative events and its expression is necessary to limit the amount of neuronal loss. These findings have been independently replicated using pre-ischemic conditioning as well as gene transfer methods. 54, 55 It is therefore likely that, while low (physiological) levels of IL-1 allow the maintenance of neuronal plasticity in the adult brain, excessive and sustained production of IL-1, which can occur within 30 min following brain injury, dramatically impairs not only neuronal, but also non-neuronal cell functions.
The gene encoding for IL-1ra is expressed in neurons in physiological conditions; neurons may therefore exhibit some resistance to direct, neurotoxic actions of IL-1. Thus, the level of constitutive IL-1ra expression and the rate and extent of its synthesis after damage may significantly influence the sensitivity of specific neurons to insults which induce IL-1 synthesis. Understanding the mechanisms of induction of IL-1ra and IL-1 expression in the brain after injury may therefore offer therapeutic benefit for the treatment of neurodegenerative disorders. The search for endogenous neuroprotective molecules represents a promising therapeutic strategy for neurodegeneration. This is of relevance to the biology of the medical consequences of major depression. Sheline et al 56, 57 have shown atrophy of the hippocampus and amygdala in major depression. Such atrophy was positively correlated with duration of depression and could be due either to the effects of glucocorticoids or to CRH. Next, we will summarize studies testing the hypothesis that corticotropin releasing hormone (CRH) in excessively high levels might be directly neurotoxic to the CNS.
Does CRH-mediated neurotoxicity contribute to the somatic manifestations of major depression?
In collaboration with Nancy Rothwell's group, we have conducted experiments that showed that in ischemic cortex, CRH mRNA levels were elevated 2.6-fold 60 min after MCAo, when compared to sham-operated animals. CRH mRNA was also induced ispilaterally in the amygdala, 60 min following ischemia, in a pattern which was qualitatively different from that of shamoperated animals. 42 This finding, when interpreted in the light of previous studies showing neuroprotection by CRH antagonists in animal models of acute ischemia, 58, 59 led to the concept that high levels of endogenous CRH may contribute to neurotoxicity. [60] [61] [62] anorexia nervosa 63 and Alzheimer's disease. 64 Interestingly, these diseases are characterized by cognitive alterations. It remains to be determined whether the cognitive symptoms present in those disorders are related to changes in central CRH levels. The evidence that increased CRH may be associated with neurotoxicity provides additional rationale to investigate the usefulness of drugs affecting CRH function in the treatment of those disorders.
Are CRH/IL-1 interactions, occurring in extrahypothalamic circuits, relevant to the biology of major depression?
IL-1ra is an endogenous neuroprotective agent while high levels of extrahypothalamic CRH are neurotoxic. Evidence suggests that a variety of endogenous molecules can either be neuroprotective or can lead to neurodegeneration. Hence, it is likely that the net ratio of CRH/IL-1ra might impact on the fate of CNS neurons. Higher levels of IL-1ra might facilitate neuronal survival, while excessive levels of CRH might lead to neuronal death. In atrophy of hippocampus and amygdala that has been described in depression, 56, 57, 65 such atrophy could be due to effects of glucocorticoids or to CRH. The hypothesis that a high CRH-IL-1ra ratio during the course of major depression contributes to neuronal loss in hippocampus and possibly in other brain areas should be tested, in postmodern studies.
Regulation of brain IL-1 bioactivity during systemic inflammation
In order to understand the biology of IL-1 in the brain it is necessary to review how inflammatory processes regulate central IL-1 function.
How is IL-1 bioactivity regulated in the brain during inflammation?
The concept that cytokines acting within the brain may regulate key elements of the CNS response to peripheral inflammation has been substantiated by the findings that those responses can be attenuated or even in some cases abolished by central administration of IL1ra. 28, 66 The induction of CRH gene expression in the PVN in response to peripheral lipopolysaccharide administration can be abolished by the central, but not peripheral, administration of IL-1ra, suggesting that the actions of IL-1␤ within the brain are required for CRH mRNA induction during peripheral inflammation. 66 The CNS responds to systemic inflammation with pronounced IL-1␤ gene expression and limited IL-1ra, IL-10, and IL-13 gene expression. 67 This pattern occurs throughout the CNS, including areas such as the subfornical organ, pineal gland, neurohypophysis, and hypothalamus. In contrast, in peripheral tissues, including the anterior pituitary, limited IL-1␤ gene expression but marked induction of the mRNA encoding for the secreted isoform of IL-1ra, sIL-1ra have been found. These findings on IL-1␤ induction are concordant with reports on IL-1 bioactivity after LPS treatment. 68, 69 Based on all available evidence, we have concluded that the central and peripheral cytokine compartments are integrated but differentially regulated (see Figure  1 ). Central manifestations of peripheral inflammation are mediated by endogenous brain IL-1␤ synthesized during systemic inflammation in the context of limited central cytokine counter regulation of IL-1 bioactivity. Implications of these findings are the following: (1) The different patterns of central and peripheral IL-1 counter regulation may be the result of evolution. During systemic inflammation it is advantageous to counter regulate IL-1 action in peripheral body fluids, thus limiting the inflammatory response. On the other hand, it has been suggested that it may be advantageous not to counter regulate the actions of IL-1 in the brain, as those actions cause sickness behavior, leading to sleep, decreased search for food, inhibition of reproduction, and suppression of locomotion and exploration, thereby diminishing the likelihood of confrontation with predators and facilitating recovery. (2) The CNS transcription of the HIV-1 replication factor IL-1␤ in the context of limited transcription of the IL-1 replication inhibitors IL-1ra, IL-10, IL-13 might help explain the negative impact of systemic inflammation on the clinical course of AIDS. (3) IL-1ra may be secreted by the anterior pituitary as a systemic anti-inflammatory hormone that is released in response to IL-1␤ originating from multiple sources.
Medical relevance of high IL-1␤/IL-1ra mRNA ratio in the brain during systemic illness
IL-1␤ is a potent stimulus to inducible nitric oxide synthase (iNOS) transcription and activity. IL-1 has been shown to induce iNOS mRNA and NO production in vascular and brain cells in vitro 70 and to induce iNOS in vivo. The effects of IL-1 on iNOS mRNA are stimulated by tyrosine kinase, potentiated by eicosapentaenoic acid, and inhibited by angiotensin II, actinomycin D, cyclohexamide, transforming growth factor-beta 1 (TGF-␤1), and insulin-like growth factor 1 (IGF-1). The biological effects of IL-1 are a reflection of the local ratio of IL-1␤ and of cytokines that inhibit IL-1 action. Therefore, high IL-1␤/IL-1ra mRNA in the brain during systemic inflammation, could explain the pathophysiologically significant iNOS gene transcription and bioactivity induction described in the brain during systemic inflammation. Detailed neuroanatomical studies revealed that early in the course of systemic inflammation there is a profound induction of iNOS mRNA in vascular, glial, and neuronal structures of the rat brain. 71, 72 Two neuronal hypothalamic nuclei showed strikingly high induction of iNOS mRNA: PVN and the arcuate nucleus. iNOS mRNA levels were also markedly induced in both endocrine glands that are situated in close proximity to the brain, the pituitary and the pineal. McCann et al have proposed that repeated infections throughout life result in bouts of iNOS expression, high level of NO production, and cytotoxicity, whose cumulative effect across the life span contributes to the aging process. 73 During systemic inflammation, iNOS gene expression was accompanied by the production of nitric oxide (NO) metabolites in brain parenchyma and cerebrospinal fluid (CSF). The spillover of NO metabolites, such as nitrites, into the CSF has the potential to be a diagnostic marker for systemic inflammation and sepsis. Thus, the metabolic byproducts of cytokine action within the brain may be of diagnostic relevance in human disease.
IL-1␤ induced iNOS might contribute to brainimmune interactions
Temporal and spatial patterns of IL-1␤, IL-1RI, and iNOS gene expression in vascular and peri-vascular areas of the rat brain during the course of LPS-induced systemic inflammation have been examined. 52 As we have noted, IL-1R1 is constitutively expressed at the interface of the vascular wall, and perivascular glia. During systemic inflammation there is induction of IL-1␤ gene expression in the vascular wall, accompanied by perivascular induction of iNOS mRNA. During systemic inflammation, vascular IL-1␤, binding to vascular and perivascular IL-1R1 receptors, may induce perivascular iNOS gene expression, leading to the production of NO and modulation of the effects of IL-1␤ in the brain (Figure 2 ). Vascular and perivascular induction of iNOS mRNA by IL-1␤ might represent a mechanism for the modulation of the CNS effects of peripheral inflammatory mediators. 20 It is very likely that other barrier-related sites can also contribute to the actions of cytokines in the CNS. 20, 48 It is important to emphasize that the hallmarks of cytokine biology are pleiotropism and redundancy. Thus, there seems to be redundant pathways by which circulating IL-1␤ acting on vascular and perivascular IL-1 type I receptors signals the brain. In addition to iNOS induction, vascular IL-1RI activation causes induction of COX-2 resulting in prostaglandin synthesis (Figure 2) . 48 These different lines of evidence seem to indicate that during peripheral inflammation IL-1 acts within the brain to mediate sickness behaviors induced by peripheral cytokines. However, because the signaltransducing type I IL-1 receptor has not been identified in brain areas whose activities are modulated by IL-1␤, it is difficult to explain how central IL-1␤ might mediate these effects at the cellular and molecular levels. Thus, this key question in the field remains unanswered. In response to peripheral inflammation, peripheral cytokines such as IL-1␤ are synthesized and may circulate in the blood stream. This is followed by the synthesis of IL-1␤ in key areas of the brain, such as the PVN, which potently respond to that cytokine; however, IL-1 receptors do not seem to be present in those areas. There might be three explanations for this interesting paradox. First, it is possible that novel IL-1 receptors exist in brain. However, in spite of considerable effort by several groups, such receptors have not been identified or cloned. Second, because IL-1 receptors are downregulated by inflammation, it is possible that existing studies have not identified IL-1RI in the PVN because previous studies were not specifically designed to rigorously eliminate infection or inflammation as confounding variables; however, this is unlikely in the light of previous studies that have been rigorously conducted. 48 Alternatively, it is possible that IL-1␤, acting in: (1) areas that send inputs to the PVN; (2) areas that are adjacent to the PVN; or (3) at the level of brain vasculature 52 within the PVN, might cause the generation of other informational molecules, such as prostanoids 48, 74 or NO, 75 that would modulate the effects of IL-1 on PVN function. Thus, it is possible that IL-1 synthesis and actions may occur in areas, such as the PVN, that apparently lack IL-1 receptors. IL-1 binding to receptors localized in sites other than PVN neurons would stimulate the production of prostanoids or NO; those molecules would than mediate the effects of IL-1␤ on PVN neurons. IL-1␤ synthesized by the PVN might not act directly at that site, and could be instead secreted into hypophyseal portal blood as a hypothalamic neurohormone that regulates pituitary function. IL-1␤, in levels that are achieved in the circulation during inflammation, directly stimulates pituitary cells to secrete ACTH, LH, GH, and TSH, and inhibits the secretion of prolactin. 76 These pituitary effects have led Bernton and colleagues to propose that IL-1, acting directly at several sites that include the pituitary gland, may be an important regulator of the metabolic adaptations to infectious stressors. The pituitary is particularly responsive to IL-1␤ during stress or inflammation because CRH, a hormone that is synthesized by the PVN and secreted into hypophyseal portal blood, induces the expression of IL-1RI receptors in the pituitary gland, 77 thereby increasing the pituitary responsiveness to IL-1␤.
During sytemic inflammation, key areas that drain to the anterior pituitary, such as PVN, arcuate nucleus, median eminence, and posterior pituitary all express high levels of IL-1␤ mRNA, while the anterior pituitary expresses moderate levels of IL-1␤ followed by very high levels of expression of the mRNA for the secreted isoform of IL-1ra, sIL-1ra, which is known to be induced by IL-1␤. The pituitary secretion of IL-1ra might represent a novel systemic hormonal antiinflammatory mechanism that is elicited during systemic inflammation by IL-1␤ that reaches the anterior pituitary originating from multiple sources that include PVN, arcuate nucleus, median eminence, posterior pituitary, systemic circulation, and the anterior pituitary itself. 67 It has been recently demonstrated by Reichlin and colleagues, that the brain and/or its supporting structures are activated by intracerebroventricular IL-1␤ to release IL-6 into the blood and that such an effect is not dependent on peripheral sympathetic activity or central mobilization of CRH. Direct secretion of IL-6 and possibly of other cytokines from the brain has been postulated to be a pathway of neuroimmunomodulation 78 in much the same way that the hormonal cascade released from the hypothalamic-pituitary-adrenal axis modulates peripheral endocrine effects. Thus, the relationship between peripheral and central cytokines is such that peripheral cytokines, originating from immune cells, affect the functioning of the brain, and central cytokines may be secreted by the brain to modulate peripheral immune function. . the peak of induction for IL-1␤ gene expression at 30 min represented an increase of 100% over baseline conditions (P Ͻ 10 −4 ); the levels of IL-1␤ mRNA returned to baseline after 1 h of the beginning of immobilization stress, remaining unchanged thereafter. We examined the spatial pattern of IL-1␤ gene expression by studying coronal brain slices collected at every 1 mm and we could not detect IL-1␤ gene induction in the rest of the CNS at 30, 60, or 120 min after the initiation of immobilization stress. Our results are not concordant with the results from Minami et al obtained using RT-PCR for IL-1␤. 79 We also studied the contribution of glucocorticoids to the expression of IL-1␤ gene in the paraventricular nucleus of the hypothalamus (PVN). We found that IL-1␤ gene expression was induced with a peak at 2 h in the PVN and meninges in adrenalectomized animals which received a physiological dose of corticosterone replacement and that were submitted to acute immobilization stress when compared to sham-operated animals ( Figure 3 ). Therefore, high levels of endogenous corticosteroids that are induced by stress blunt the induction of IL-1␤ gene expression in the PVN. In the light of the finding of Errol De Sousa's group that CRH induces IL-1RI in the pituitary, 80 the posterior pituitary production of IL-1␤ might indicate a mechanism by which stress induces CRH-IL-1 interactions in the pituitary that contribute to regulate endocrine function.
Dysregulation of HPA function is a key element in the biology of major depressive disorder. 60, 61, [81] [82] [83] As stress-induced IL-1␤ gene expression in the brain is modulated by endogenous adrenal steroids, it is possible that the outcome of major depression might be affected by the balance between HPA activation and IL-1␤ production. We propose the following model: In major depression, stress-related increased levels of IL-1␤ would stimulate HPA activity, which would in turn downregulate IL-1␤ levels; lower IL-1␤ production would then lead to decreased levels of HPA function, which would facilitate new increases in IL-1␤ synthesis and a continuation of this cycle (see Figure 4) . This reciprocal and alternating relation between IL-1␤ synthesis and HPA activation would result in a state in which neither IL-1␤ nor HPA hormones are constantly elevated. This might explain why, in spite of both HPA and IL-1 activation, patients with major depression do not present with overt clinical features of either endocrine or immune disease. Moreover, the balance between the actions of stress-related IL-1␤ and HPA hormones in major depression might modulate the medical consequences of this disorder, including decreased bone mineral density, 84 cardiovascular mor- bidity, 85 and neurodegeneration: 56, 57 these processes are regulated by IL-1␤ bioactity and by HPA hormones.
Inescapable shock studies
When the following findings are taken into account, it is tempting to propose that stress induction of IL-1␤ might contribute to the persistent activation of CRH circuitries in depression: (1) Maier and colleagues have shown that stress induces IL-1␤ bioactivity in the brain and that icv IL-1ra administration abolishes learned helplessness; 86 (2) peripheral LPS administration causes protracted increases in locus coeruleus (LC) firing rates, that can be attenuated by microinfusion of IL-1ra directly into the LC (M Borsody and J Weiss, personal communication); (3) IL-1␤ has been reported to be a potent regulator of the serotonin transporter gene, a primary target for antidepressant treatment; (4) antidepressant treatment has been shown to increase IL-1ra more than 100-fold in the hypothalamus. 87 The blocking of IL-1RI signal transduction by exogenous IL1ra administration resulting in the abolishment of learned helplessness is evidence that the IL-1␤/IL-1ra ratio is important in the pathophysiology of major depression. Moreover, the reported 100-fold upregulation of IL-1ra by antidepressants could indicate a novel mechanism for the effects of antidepressants. Based on those data, one would expect that antidepressants would decrease the IL-1␤/IL-1ra ratio. This could explain their potent effects on treating learned helplessness and on decreasing CRH gene expression in the hypothalamus, first described by our group in 1991. 88 However, we are still trying to reproduce these cytokine findings in response to stress and to antidepressant treatment. In our own lab, repeated studies using in situ hybridization have not shown that stress markedly induces IL-1␤ gene expression in brain parenchyma or that antidepressant treatment upregulates IL-1ra gene expression. Such discrepancies between our findings and those of other groups could be due to the fact that our experiments were rigorously conducted in stress-, virus-, and antibody-free animals. It is possible that the combined effects of inflammation and stress or antidepressant treatment are necessary to elicit the reported effects on IL-1␤/IL-1ra mRNA and bioactivity. Morever, differences in techniques could contribute to those different results. Those issues can only be conclusively resolved by collaborative studies among various groups, using shared materials and standardized research protocols.
Limitations, pitfalls and strategies
The study of cytokine action in the brain has been hindered by a virtual absence of stable, nonpeptide receptor agonists and antagonists, the species specificity of some cytokines, and a very low constitutive expression of most of these molecules and their receptors. Complications also arise from discrepancies between bio-and immunoassays, which may be resultant of the presence of naturally occurring inhibitors, binding proteins, and soluble receptors in many tissues and extracellular fluids. Bio-and immunoassays are available for most cytokines. The immunoassays are generally speciesspecific, and there is a notable scarcity of recombinant cytokines and antibodies for the rat. 89 While immunologists work with either human or mouse tissue, most of the classical and functional neuroanatomical and neuroendocrinological studies have used the rat as an experimental animal. Most research groups are now progressing towards the inclusion of the mouse as an experimental animal, because the availability of transgenic animals makes it possible to conduct mechanistic studies on the role(s) of specific cytokines.
Conclusions
In conclusion, we have reviewed evidence that cytokines in the brain are: (1) constitutively expressed; (2) can have non-immune functions such as neuroprotection; and (3) can be regulated by non-immune stressors. Cytokine activation in the brain or in the periphery may be the result of stress, aseptic inflammation, or neurodegeneration. Therefore, induction of central or peripheral cytokines is not necessarily an indication of autoimmunity. Thus, previous studies that assumed that variations in cytokine levels in psychiatric patients are evidence of autoimmunity have to be reexamined. Such data can be interpreted as evidence that in psychiatric disorders cytokine expression might reflect either a primary or secondary event related to neurogeneration, stress, or intermittent inflammation. Existing data do not rule out the possibility of autoimmunity in psychiatric disorders but indicate that alterations in cytokine expression in those disorders is not synonymous with autoimmunity. When data from studies that examine central and peripheral cytokine levels in depression or other disorders are examined, it is crucial to take into consideration the concept that the central and peripheral cytokine compartments are integrated but differentially regulated.
Even though an association between psychiatric symptoms and inflammation has been known for a century, a mechanistic understanding of the contributions of immune mediators to the pathogenesis, pathophysiology, and treatment of psychiatric disorders is in its infancy. Researchers are now examining the fundamental neurobiology and the relevance to major depression of neuroimmune molecules that are a major regulator of stress-responsive systems. Currently available evidence indicates that CNS cytokines, especially the IL-1 system, may have a role in the biology and somatic consequences of major depession, as well as in the effects of antidepressant treatment. This is not surprising because several key functions that have been related to the CNS actions of cytokines, such as sleep, food intake, body weight regulation, cognition, behavior, temperature and neuroendocrine transduction, 20 are known to be dysregulated in major depression. In the next article in this issue Dantzer and colleagues provide further discussion on the role of cytokines in depressive disorder, 90 and in a News & Views and accompanying Image in this issue, PlataSalamán and Turrin discuss in broader terms the role of CNS cytokines in neurological and psychiatric disorders. 91, 92 
